Full Press Release Details
Announces Pricing of Follow-On Offering
NEW YORK--(BUSINESS WIRE)--April 4, 2018--Regulatory News:
Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS - EURONEXT
GROWTH: ALCLS), a clinical-stage biopharmaceutical company focused on
developing immunotherapies based on gene-edited allogeneic CAR T-cells,
announced that the price of its offering of American Depositary Shares
("ADS") launched on April 3, 2018, has been set today at $31.00 per ADS
and that the number of offered ADSs is 5,646,000. In connection with the
offering, Cellectis granted the underwriters a 30-day option to purchase
up to an additional 846,900 ADSs. The closing of the offering is
expected to occur on April 10, 2018, subject to customary closing
conditions. The listing of the ordinary shares of Cellectis on Euronext
Growth will be suspended on April 5, 2018 until the opening of trading
on the Nasdaq market at 3:30 pm (Paris time).
Goldman Sachs & Co. LLC, Citigroup and Barclays are acting as
book-running managers for the offering. Nomura is acting as lead manager
and Oppenheimer & Co. and Ladenburg Thalmann are acting as co-managers.
A shelf registration statement on Form F-3 (including a prospectus)
relating to Cellectis' American Depositary Shares was filed with the
Securities and Exchange Commission (the "SEC") and has become effective.
Before purchasing American Depositary Shares in the offering, you should
read the prospectus supplement and the accompanying prospectus, together
with the documents incorporated by reference therein. You may obtain
these documents for free by visiting EDGAR on the SEC's website at www.sec.gov.
Alternatively, a copy of the prospectus supplement (and accompanying
prospectus) relating to the offering may be obtained from Goldman Sachs
& Co. LLC, Attention: Prospectus Department, 200 West Street, New York,
NY 10282, or by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com,
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by telephone at (800)
831-9146 or Barclays Capital Inc., c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at
(888) 603-5847 or by email at barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. In particular, no public offering of the ADSs will be made
Special Note Regarding Forward-Looking Statements
This press release contains "forward-looking" statements that are based
on our management's current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements.
Further information on the risk factors that may affect company business
and financial performance is included in Cellectis' Annual Report on
Form 20-F for the year ended December 31, 2017, and subsequent filings
Cellectis makes with the SEC from time to time. Except as required by
law, we assume no obligation to update these forward-looking statements
publicly, or to update the reasons actual results could differ
materially from those anticipated in the forward-looking statements,
even if new information becomes available in the future.
VP of Communications
Kasunich, 212-896-1241
KCSA Strategic Communications
Simon Harnest, 646-385-9008
VP of Corporate Strategy